TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSN-084’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TSN-084 overview

TSN-084 is under development for the treatment of advanced malignant tumors, solid tumors including triple-negative breast cancer and non-small cell lung cancer and acute myeloid lymphoma (AML). The drug candidate is administered through oral route in the form of tablets and acts by targeting CDK8/19, MET, AXL, FLT3 and NTRK.

Tyligand Biotechnology (Shanghai) overview

Tyligand Biotechnology (Shanghai) (Tyligand Biotechnology) is a drug research and development company. Tyligand Biotechnology is headquartered in Shanghai, China.

For a complete picture of TSN-084’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.